Logo

• Open gynecological cancer (KGOG3066)

  A multicenter, open-label, single-arm, phase 2 study to evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer patients previously treated with a PARP inhibitor

  • PI / PI기관 Sokbom Kang /
  • Registration Date / Last Update Posted 2023-03-14 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 18 person / 58 person (31.0%)

• Open gynecological cancer (KGOG4003)

  CIEL: Association of cul-de-sac seeding with intraperitoneal tumor burden in advanced ovarian cancer

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 59 person / 100 person (59.0%)

• Open gynecological cancer (KGOG3060)

  Effectiveness of Routine Intensive CA125 Monitoring in Ovarian Cancer: A Pragmatic Randomized Study

  • PI / PI기관 Sokbom Kang /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-02-18
  • Current Enrollment / Estimated Enrollment 6 person / 74 person (8.0%)

• Open gynecological cancer (KGOG3059)

  A cohort study to assess the safety and efficacy of PARP inhibitor maintenance after first-line therapy of Korean women with advanced ovarian/fallopian/peritoneal cancer

  • PI / PI기관 Eun-Ju Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 6 person / 1000 person (0.6%)

• Open gynecological cancer (KGOG3058)

  ESPOIR: Effectiveness and safety of PARP-inhibitor therapy in recurrent ovarian cancer patients in real world; Ambidirectional multicenter cohort study (JGOG3026 RESPONSE study와 추후 Data 공유 예정)

  • PI / PI기관 Hyun Jin Choi /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 78 person / 427 person (18.0%)

• Open gynecological cancer (KGOG3056)

  A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor

  • PI / PI기관 Jung-Yun Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 25 person / 44 person (57.0%)

• Open gynecological cancer (KGOG3055)

  JGOG3024: Prospective cohort study of variant carriers with BRCA1 and BRCA2

  • PI / PI기관 Jae-Weon Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-02-18
  • Current Enrollment / Estimated Enrollment 11 person / 600 person (1.7999999999999998%)

• Open gynecological cancer (KGOG3049)

  Phase II trial evaluating the Efficacy and safety of physician chosen chemotherapy with hormonaL therapy in patientS with heavily pretreated Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer: A multicenter pilot study (ELSA)

  • PI / PI기관 Bang Hyun Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 23 person / 58 person (40.0%)

• Open gynecological cancer (KGOG3035)

  JGOG3020: A phase III randomized clinical trial to investigate the necessity of adjuvant chemotherapy for surgical stage I epithelial ovarian cancer

  • PI / PI기관 Jae-Weon Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 258 person / 360 person (71.7%)

• Open gynecological cancer (KGOG2030)

  Development of biomarker predicting high dose progesterone therapy in reproductive aged women with early-stage endometrial cancer

  • PI / PI기관 Jung-Yun Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 138 person / 300 person (46.0%)

* (사)대한부인종양연구회는 게시된 세부 임상연구 정보에 대해 법적 책임이 없습니다.